2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-173556
    GPR84 agonist-2 3105662-82-3 99.80%
    GPR84 agonist-2 is a selective GPR84 agonist with no activity at free fatty acid receptors. GPR84 agonist-2 enhances GPR84-mediated signaling above basal levels and potentiates agonist-induced GPR84 activation. GPR84 agonist‑2 can be used for research on GPR84-related physiological mechanisms.
    GPR84 agonist-2
  • HY-17363S
    Dimethyl fumarate-d6 66487-95-4 99.9%
    Dimethyl fumarate-d6 is a deuterium labeled Dimethyl fumarate. Dimethyl fumarate is a nuclear factor (erythroid-derived)-like 2 (Nrf2) pathway activator and induces upregulation of antioxidant gene expression.
    Dimethyl fumarate-d6
  • HY-17386S
    Rosiglitazone-d3 1132641-22-5
    Rosiglitazone-d3 is the deuterium labeled Rosiglitazone. Rosiglitazone (BRL 49653) is a selective, orally active PPARγ agonist with EC50s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively. Rosiglitazone binds to PPARγ with a Kd of approximately 40 nM. Rosiglitazone is also an activator of TRPC5 (EC50=~30 μM) and an inhibitor of TRPM3.
    Rosiglitazone-d3
  • HY-17479A
    Amfenac Sodium Hydrate 61618-27-7 98.33%
    Amfenac Sodium Hydrate is a COX-2 inhibitor.
    Amfenac Sodium Hydrate
  • HY-174903
    ITK-IN-6 2616666-32-9 99.02%
    ITK-IN-6 is a highly potent and selective ITK inhibitor (Kd = 387 nM). ITK-IN-6 directly binds to the ITK kinase domain. ITK-IN-6 blocks the release of pro-inflammatory cytokines and the activation and differentiation of Th2 and Th17 cells. ITK-IN-6 improves asthma progression by reducing inflammatory cell infiltration, mucus and IgE production. ITK-IN-6 significantly inhibits airway inflammation and is used in asthma research.
    ITK-IN-6
  • HY-175547
    PROTAC HPK1 Degrader-5 3108744-13-1 98%
    PROTAC HPK1 Degrader-5 is a potent and orally active HPK1 PROTAC degrader (DC50 = 5.0 nM; Dmax ≥ 99%). PROTAC HPK1 Degrader-5 significantly inhibits SLP76 phosphorylation and enhanced ERK pathway activation through degrading HPK1, thereby stimulating IL-2 and IFN-γ release. PROTAC HPK1 Degrader-5 exhibits the ability to overcome the immunosuppressive effects imposed by PGE2, NECA or TGF-β. PROTAC HPK1 Degrader-5 alone efficaciously inhibits tumor growth in an MC38 syngeneic mouse model. PROTAC HPK1 Degrader-5 can be used for the study of tumor (such as colorectal cancer) immunotherapy (Pink: Target protein ligand (HY-175549); Blue: E3 ligand (HY-W023573); Black: Linker; E3 ligand + Linker (HY-175551)).
    PROTAC HPK1 Degrader-5
  • HY-175714
    STING agonist-46 3033532-05-4 98.63%
    STING agonist-46 is an orally active STING agonist. STING agonist-46 activates the STING signaling pathway, promoting phosphorylation of TBK1 and IRF3, and secretion of IFN-β and IP-10. STING agonist-46 directly binds to STING and increases its thermal stability. STING agonist-46 demonstrates potent anti-tumor efficacy in B16F10, CT26, and 4T1 mouse models. STING agonist-46 can be used for cancer immunotherapy studies.
    STING agonist-46
  • HY-176039
    TUG-2181 2653994-24-0 98.20%
    TUG-2181 is an antagonist of GPR84 with an IC50 value of 34 nM. TUG-2181 inhibits GPR84 agonists-induced reactive species oxygen (ROS) production and IL-8 release in human neutrophils. TUG-2181 can be used for inflammation and fibrosis study.
    TUG-2181
  • HY-176192
    SMU-14a 98%
    SMU-14a is a selective Toll-like receptor 3 (TLR3) inhibitor wirh an IC50 of 0.18 μM. SMU-14a reduces phosphorylation of p65, ERK, and TBK1 via NF-κB, MAPK, and IRF3 signaling pathways. SMU-14a inhibits IL-6 secretion in mouse peritoneal macrophages, downregulates TNF-α in human peripheral blood monocytes and decreases serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. SMU-14a can be used for the research of acute hepatitis.
    SMU-14a
  • HY-176224
    Anti-virulence factor-IN-2 98.41%
    Anti-virulence factor-IN-2 (compound C7) is an inhibitor targeting the virulence factor KpsM in Escherichia coli. kpsM mediates the translocation of capsular polysaccharides to the cell surface, allowing kpsM-positive E. coli to escape the phagocytosis of the scavenger receptor Marco on liver Kupffer cells, leading to bacterial dissemination. kpsM-positive E. coli exacerbates ethanol-induced liver disease. Anti-virulence factor-IN-2 can inhibit the ethanol-induced liver disease model caused by kpsM-dependent capsid in mice and has anti-infective activity. Anti-virulence factor-IN-2 can be used for the study of alcoholic hepatitis.
    Anti-virulence factor-IN-2
  • HY-176402
    Dyrk1A-IN-13 99.43%
    Dyrk1A-IN-13 (Compound 1) is a DYRK1A inhibitor (IC50: 41 nM). Dyrk1A-IN-13 reduces LPS-induced NO production and has antioxidant and anti-inflammatory activities. Dyrk1A-IN-13 can be used in the research of Alzheimer's disease, cancer and diabetes.
    Dyrk1A-IN-13
  • HY-176753
    Lipid 20b 2921586-65-2 98.7%
    Lipid 20b is a thiophene ionizable cationic lipid. Lipid 20 b can be used to generate lipid nanoparticles (LNPs) for the delivery of mRNA in vivo. Lipid 20b can be studied in research for enhancing mRNA vaccine delivery and transfection efficacy.
    Lipid 20b
  • HY-176778
    BDM88951 2790420-60-7
    BDM88951 (Compound 4 d) is a selective ERAP2 inhibitor with an IC50 of 19  nM. BDM88951 significantly inhibits antigen presentation. BDM88951 can be used for autoimmune diseases and cancers research.
    BDM88951
  • HY-176851
    GSK1362 2986733-57-5
    GSK1362 is a selective inverse agonist of REV-ERB. GSK1362disrupts the interaction of REV-ERBα with repressive co-modulators (NCoR1, SMRT2, RIP140). GSK1362 exerts an inverse agonist effect by increasing the transcription of BMAL1 to relieve BMAL1 repression by endogenous REV-ERB ligands. GSK1362 suppresses LPS (HY-D1056)-induced inflammatory cytokine expression, inhibits IL-1β-induced Cxcl5 transcription in cells. GSK1362 can be used for the study of inflammatory diseases.
    GSK1362
  • HY-176862
    TCB-32 352513-86-1 98%
    TCB-32 (Compound I-1) is a FGFR1 agonist with an EC50 of 0.88  μM. TCB-32 significantly increases cell proliferation through activating FGFR1 signaling pathway as bFGF and its downstream ERK1/2 with excellent thermal stability. TCB-32 can replace bFGF in serum-free cell culture media. TCB-32 can be used for tissue repair and wound healing related diseases like psoriasis and eczema research.
    TCB-32
  • HY-176990
    TP receptor antagonist-3 165537-72-4 99.88%
    TP receptor antagonist-3 (compound 51280) is a potent thromboxane A2 prostanoid (TP) receptor with an IC50 of 15.7 nM against Human TP. TP receptor antagonist-3 can be used for alzheimer's disease, cardiovascular and respiratory diseases, and cancer research.
    TP receptor antagonist-3
  • HY-177063
    IL-6-IN-2 296790-70-0 99.95%
    IL-6-IN-2 is an interleukin-6 (IL-6) inhibitor. IL-6-IN-2 binds to IL-6 at Lys66, Phe74, Gln175, Ser176, and Arg179 via π-π, π-alkyl, hydrogen bond, and hydrophobic interactions to block IL-6/IL-6R heterocomplex formation. IL-6-IN-2 exhibits low gastrointestinal absorption rate. IL-6-IN-2 can be used for the research of cytokine release syndrome, covid-19.
    IL-6-IN-2
  • HY-177119
    ZBP1 Covalent PROTAC-1
    ZBP1 Covalent PROTAC-1 is a covalent Z-DNA binding protein 1 ZBP1 PROTAC degrader, with its DC50 being 25.69 nM. ZBP1 Covalent PROTAC-1 integrates the ligand that recruits the VHL E3 ubiquitin ligase and the DNA aptamer (Aptamer Z3) with the specific Zα domain that can bind to ZBP1, which has a high affinity (KD = 2.71 nM) with ZBP1. After degrading ZBP1, the phosphorylation levels of downstream signaling molecules RIPK3 and MLKL significantly decrease. ZBP1 Covalent PROTAC-1, encapsulated by nano-liposomes, significantly improves the survival rate of mice infected with influenza A virus (IAV) after administration via the trachea.
    ZBP1 Covalent PROTAC-1
  • HY-177414
    BB-1701 98.81%
    BB-1701 is an anti-HER2 antibody-drug conjugate (ADC). BB-1701 is composed of a humanized anti-HER2 antibody (Trastuzumab) (HY-P9907), a linker (Mal-PEG2-VCP), a microtubule inhibitor (Eribulin) (HY-13442), and the drug-linker conjugate for ADC is Mal-PEG2-VCP-Eribulin (HY-128870). BB-1701 has a potent cytotoxicity and bystander effects on tumors with heterogeneous target expression. BB-1701 significantly induces immunogenic cell death and the activation of the immune.
    BB-1701
  • HY-177515
    IRAK4 modulator-2 1356013-27-8 99.86%
    IRAK4 modulator-2 (Compound 5) is a selective dual Interleukin-1 Receptor Associated Kinase 4 (IRAK4) and IRAK1 inhibitor with IC50 values of 0.005 μM and 0.97 μM, erespectively. IRAK4 modulator-2 blocks IRAK-mediated signaling pathways (e.g., JAK-STAT, NF-κB pathways), reduces the production of pro-inflammatory cytokines (e.g., IL-1, TNF), and exerts anti-inflammatory activity. IRAK4 modulator-2 is promising for research of autoimmune diseases and inflammatory diseases, such as rheumatoid arthritis, psoriasis, inflammatory bowel disease.
    IRAK4 modulator-2
Cat. No. Product Name / Synonyms Application Reactivity